Brodalumab is a human, monoclonal antibody administered by subcutaneous injection that targets the IL-17 receptor (IL-17RA) and subsequently inhibits binding of several IL-17 cytokines including ...
The experimental monoclonal antibody brodalumab, an interleukin 17 (IL-17) receptor antagonist, achieved a 100% reduction in plaque psoriasis symptoms in twice as many patients as the commonly used ...
Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE registry ...
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...
Broad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential ...
The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...
Everyday Health on MSN
Why do psoriasis treatments sometimes stop working?
Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback